The Centers for Disease Control and Prevention frequently receives inquiries from health care providers, public health officials, and the general public seeking data or guidance on vaccinesafety issues. Past inquiries to public health authorities identified potential problems including viscerotropic illness rarely associated with yellow fever vaccination.
As vaccination-coverage rates increase and the incidence of vaccinepreventable disease decreases, the number of reported adverse events (AEs) temporally associated with vaccines increases. In addition, public concern for AEs also tends to increase. 1 In addition to reducing the burden of vaccine-related injury, close attention to vaccine safety helps secure public support for vaccination programs and helps to increase uptake of vaccinations. 2, 3 The Vaccine Adverse Event Reporting System (VAERS) is a federally mandated passive surveillance system that accepts reports of AEs that have a temporal association with US-licensed vaccines. 1 VAERS accepts reports from the United States and elsewhere. It is managed by the Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration. VAERS plays a central role in detecting "signals" for vaccine-safety problems that require further investigation by means of more systematic studies. However, VAERS has a number of limitations including underreporting. 1, [4] [5] [6] Most of the (AE) reports are voluntary and depend on potential reporters' recognizing that a problem may be vaccine related, which is often not an easy task. 7 Underreporting limits our ability to analyze and detect possible associations between vaccines and AEs. Failure to fully capture cases can cause potential indications of previously unknown side effects to be missed. 8, 9 In addition, more common AEs may be undercounted. Serious AEs are more likely to be reported than those that are less serious, but reporting of any AE depends, in large part, on alert health care providers. 7, 9 Serious AEs are defined by the Food and Drug Administration as those that result in death, life-threatening illness, hospitalization, prolongation of an existing hospitalization, or permanent disability.
In addition to VAERS reporting, the CDC uses several other methods to study vaccine safety, including the Vaccine Safety Datalink and the Clinical Immunization Safety Assessment (CISA) Network. These activities reside in the CDC Immunization Safety Office (ISO) and have been described elsewhere. 10, 11 Briefly, the Vaccine Safety Datalink is a collaborative effort between the CDC ISO and 8 large linked databases to monitor vaccine safety by performing population studies that use data from electronic medical records. The CISA Network is a collaborative effort between the CDC ISO and 6 medical research centers to conduct clinical research on vaccine AEs on the individual patient level.
Inquires to federal agencies prompted investigations into possible links between vaccines and health problems before the start of the Inquiry Tracking System (ITS), including recognition of viscerotropic illness associated with yellow fever vaccine 12 (which led to enhanced surveillance for AEs after yellow fever vaccine, dissemination of information to certified yellow fever vaccination centers, and a label change for the yellow fever vaccine) and the possible association of alopecia with the hepatitis B vaccine. 13 In May 2002, the CDC ISO developed the ITS to systematically monitor all the inquiries it received to augment reporting to VAERS, to identify issues that need further investigation, and to detect emerging trends in vaccine-safety concerns. In this report we describe the initial results of the CDC ITS.
METHODS
The CDC ISO receives inquiries from a variety of sources. The 2 primary sources of immunization-related inquiries are the CDC telephone information line (1-800-CDC-INFO/1-800-232-4636) and the CDC vaccine e-mail account (nipinfo@cdc.gov [NIPINFO is the commonly used term for the National Immunization Program e-mail account]). 14, 15 The CDC telephone hotline is an integrated information line through which callers can ask questions on any health topic including immunization. The staffers on this hotline have access to information prepared by CDC immunization experts. In addition, health care providers who staff this hotline are also available to answer the more complex or unusual types of questions. The CDC NIPINFO e-mail account, staffed by physicians, nurses, and health education specialists who are experts in the immunization field, answer immunization questions by e-mail from both laypersons and health care professionals. Vaccine-safety questions that cannot be answered by staff members of these services are often referred to ISO staff-physicians, nurses, and epidemiologists who are experts in the field of vaccine safety. They have direct access to VAERS and other sources of safety data. The ISO also receives questions, usually via e-mail, from a variety of other sources (see Fig 1) .
An Access (Microsoft, Redmond, WA) database is used to record inquiries that reach the ISO. Questions are recorded in their entirety and then categorized according to source, mode of communication, and general topic of the question and according to vaccine or AE. Responses to inquiries are also recorded in their entirety. Questions about AEs prompt searches for similar previous queries to both detect patterns and prepare consistent responses. ISO staff members were requested to copy all responses to 1 staff member who was responsible for recording the information in the ITS. We analyzed all inquiries received between May 1, 2002, and May 31, 2009, for the reason for the inquiry, inquiry subject, vaccine in question, and inquiry source. Follow-up data for clini-cal outcome or understanding of response were not routinely collected.
RESULTS
The ISO responded to 983 inquiries between May 2002 and May 2009 (ϳ11 per month). Health care workers (public, private, or military) submitted 419 queries (43%), members of the general public submitted 185 (19%), and staff from other areas of the CDC submitted 172 (17%). Staff of NIPINFO sent 142 (14%) inquiries to the ISO, and those who were manning the CDC telephone information line sent 121 (12%).
During the same time period, VAERS received a total of 142 995 US reports (data not shown), and the NIP e-mail account addressed ϳ25 to 39 inquiries per day, of which ϳ4% to 5% were related to vaccine-safety issues (NIPINFO staff, personal communications, June 29, 2009). During this time period, 142 inquiries were forwarded to the ISO from NIPINFO, which accounts for a small fraction of vaccine-safety inquiries to NIPINFO.
The 3 main reasons the ISO was contacted were to (1) obtain information regarding VAERS data (49%), (2) obtain clinical or medical advice (21%), and (3) obtain general vaccine-related information (11%) (see Table 1 ). Topics discussed most often included (1) Table 1 ).
All vaccines or childhood vaccines were most frequently mentioned in the inquiries (224 queries [20%]), followed by diphtheria, tetanus, and/or pertussis-containing vaccines (154 queries [14%] ). Queries about influenza vaccines accounted for 149 (13%) and human papilloma virus vaccines accounted for 74 (7%) of the questions (see Table 1 ).
DISCUSSION
By maintaining a record of inquiries, CDC staff members have been better able to stay informed of issues that concern the public and providers, For cases in which requestors discussed an AE after vaccination that was not reported to VAERS, CDC staff members requested them to file a VAERS report. If the requestor was not familiar with how to file the report, the CDC staff member provided information and/or assistance.
Vaccine-safety inquiries are not only addressed to the ISO. State and local health departments, primary care providers, and CDC information telephone lines and e-mail services are all involved in responding to vaccinesafety inquiries. In general, these other health organizations likely refer inquiries to the ISO that they are not capable of answering themselves, which could be because of the complex nature of the questions or because these organizations do not have data that are needed to answer a request. This selective referral introduces a bias into the inquiries received, but it does not detract from the usefulness of the ITS as a supplement to the VAERS, the The inquiries about neurologic AEs most likely reflect the public's interest in AEs that result in hospitalization, disability, or death and AEs with etiologies that are not clearly understood, even if these AEs are rare (eg, GuillainBarré Syndrome after the meningococcal vaccine).
Health care and public health workers are probably more likely to know of or be referred to the ISO, which is indicated by the highest number of questions from these groups.
The CDC maintains Web sites aimed at both the lay public and health care professionals for the purpose of health education and information. The CDC's ISO Web site (www.cdc. gov/vaccinesafety/index.html) focuses specifically on health education and risk communication related to vaccine-safety issues. One goal of the ITS is to help determine what frequently asked questions and questions and answers will be posted on the ISO Web site and will be available to the public and media. For example, the questions on sudden infant death syndrome and autism are on the site because of the public's interest in these topics. ITS analysis can help to ensure that the public is provided vaccine-safety information that is harmonized across federal agencies, manufacturers, clinicians, and state health departments.
LIMITATIONS
The ITS has several limitations. The sample of recorded safety-related inquiries is quite small compared with other more commonly used systems for inquiries, such as NIPINFO. ITS inquiries are biased toward complex questions. In addition, because relatively few questions are referred to the ISO from the CDC telephone information service or NIPINFO, most questions are probably answered before they reach the ISO and, therefore, are not recorded in the ITS. As a result, the recorded inquiries may not be representative of vaccinesafety-related concerns that are asked about most frequently. For example, autism, possibly the most publicly discussed topic in vaccine safety, was the subject of only 2% of questions in the ITS, because staff members of 1-800-CDC-INFO and NIPINFO answer autism questions before they reach the ISO. In addition, many requests could fall into more than 1 category, because the analyzed groupings are not always mutually exclusive.
CONCLUSIONS
Despite limitations, tracking vaccination inquiries has been useful. The ITS is an additional system in which to look for previously unreported AEs. It has enabled ISO staff to be more aware of vaccine-safety issues about which the public has concerns and is a resource for questions that are asked frequently. Other public health organizations should consider recording the inquiries they receive about vaccinations. Keeping records of inquiries and associated responses will help public health workers address common questions, respond to these inquiries in a consistent manner, and remain cognizant of vaccine-safety concerns of both laypersons and health care professionals.
